A higher PD-L1 expression and antigen intensity are required by TNBC patients than ER+ breast cancer patients due to the higher tumour growth rate of TNBC; the relatively high response rate of TNBC to immunotherapy may be related to its relatively higher PD-L1 expression on average [43]. This evidence concerns the gene CD274 and breast carcinoma.